Clinical efficacy of PPAR agonists in the treatment of nonalcoholic fatty liver disease
Frontiers in Pharmacology · 27.03.2026 · 17
DOI: 10.3389/fphar.2026.1775516 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 27.03.2026. Verfasst von Xiaoling Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, West China Hospital, Sichuan University, Chengdu, China. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key Research and Development Program of Sichuan Province, Chengdu Science and Technology Bureau.
Abstract (Originalsprache)
Nonalcoholic fatty liver disease (NAFLD) has become a major public health concern. Peroxisome proliferator-activated receptors (PPARs) are nuclear receptor transcription factors. PPARs are categorized into three subtypes: PPARα, β/δ, and γ. Three subtypes of PPARs play crucial roles in lipid and glucose metabolism, inflammation and fibrosis. This review summarizes randomized controlled trials on the use of PPAR agonists in the treatment of NAFLD. PPARα and PPARβ/δ agonists control circulatory lipids well, but they do not yield enough liver benefits. PPARγ agonists, particularly pioglitazone, are recommended for NAFLD treatment. PPARα/γ agonists and PPARα/β/γ agonists are plausible in the treatment of NAFLD. More clinical studies are still in need to properly unveil the efficacy of PPAR agonists in the treatment of NAFLD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, West China Hospital, Sichuan University, Chengdu, China.
- West China School of Medicine, Sichuan University, Chengdu, China.
Förderung
- Key Research and Development Program of Sichuan Province
- Chengdu Science and Technology Bureau
Zitieren
APA
Li, X., Zhang, J., Wei, B., & Tong, H. (2026). Clinical efficacy of PPAR agonists in the treatment of nonalcoholic fatty liver disease. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1775516
Vancouver
Li X, Zhang J, Wei B, Tong H. Clinical efficacy of PPAR agonists in the treatment of nonalcoholic fatty liver disease. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1775516
BibTeX
@article{Li2026,
author = {Li, Xiaoling and Zhang, Junjie and Wei, Bo and Tong, Huan},
title = {Clinical efficacy of PPAR agonists in the treatment of nonalcoholic fatty liver disease},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1775516}
}
EUVIMED